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Abstract
Allergic skin diseases, such as atopic dermatitis (AD), are clinically characterized by severe 
itching and type 2 immunity-associated hypersensitivity to widely-distributed allergens, including 
those derived from house dust mites (HDMs). Here we found that HDMs with cysteine-protease 
activity directly activated peptidergic nociceptors, which are neuropeptide-producing nociceptive 
sensory neurons, that expressed the ion channel TRPV1 and Tac1, the gene encoding the precursor 
for the neuropeptide substance P. Intravital imaging and genetic approaches indicated that HDMs-
activated nociceptors drove the development of allergic skin inflammation by inducing the 
degranulation of mast cells contiguous to such nociceptors through the release of substance P and 
the activation of the cationic molecules receptor MRGPRB2 on mast cells. This data indicates that, 
after exposure to HDM allergens, activation of TRPV1+Tac1+ nociceptor-MRGPRB2+ sensory 
clusters represents a key early event in the development of allergic skin reaction.
Altered tissue sensitivity to environmental triggers is thought to contribute to the 
development of allergic inflammation, frequently starting with type 2 (allergic) skin diseases 
such as atopic dermatitis (AD)1 during childhood. AD is a chronic relapsing skin 
inflammatory disease characterized by severe itching of the skin, eczema and 
hypersensitivity to otherwise innocuous environmental substances2. The etiology of AD is 
incompletely understood, but many factors, such as genetic or environmental elements and 
immune or structural cells are thought to contribute to the development of skin lesions2.
Aberrantly activated type 2 immunity against common sources of indoor allergens such as 
house dust mites (HDMs) and increased numbers of activated mast cells and eosinophils in 
the lesional skin2–4 might have important roles in the pathology of AD. Moreover, 80-100% 
of patients with AD are colonized with Staphylococcus aureus, compared to only 5-30% of 
healthy individuals5, and patients whose skin is colonized with exotoxin-producing S. 
aureus, such as staphylococcal enterotoxins B (SEB)4,6,7 have a higher severity of AD than 
patients who are colonized with non-toxigenic strains6. Finally, although abnormalities of 
the epidermis leading to loss of skin barrier have been reported to contribute to skin lesions 
development8,9,10, many patients with AD don’t have loss-of-function mutations of 
epidermal structural proteins such as filaggrin11–13. Therefore, the full spectrum of factors 
which contribute to skin barrier disorganization and the development of type 2 immunity and 
skin lesions remains to be determined.
The skin is innervated by an intricate network of nociceptive sensory neurons, known as 
nociceptors, with cell bodies located in the dorsal root or trigeminal ganglia14. Their primary 
function is the transmission of sensations of temperature, pain and itch in order to elicit 
Serhan et al. Page 2
Nat Immunol. Author manuscript; available in PMC 2020 April 07.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
appropriate behavioral responses such as withdrawal (to avoid tissue injury) and scratching 
(to remove irritants). Nociceptors may be involved in manifestations of AD by promoting 
itch and scratching behavior13,15, an idea supported by clinical studies showing that the 
serum of patients with AD exhibits high amounts of neuropeptides, such as the cationic 
neuropeptide substance P (SP), and that the amounts detected correlate with the severity of 
the disease15,16. While much remains to be learned about itching sensations, peripheral 
neurons also have the potential to influence immune cells and inflammatory responses17–22.
Mast cells are innate immune cells thought to be involved in allergic diseases, including AD, 
in which they recognize a specific antigen through their high-affinity receptors for IgE 
(FcεRI)23. Under homeostatic conditions, skin and peritoneal mast cells in mice specifically 
express MRGPRB2, a receptor for cationic molecules from the Mas-related G protein-
coupled receptors family24. MRGPRX2, the human ortholog of MRGPRB2, and not the 
neurokinin 1 receptor, is the main receptor for cationic molecules, including SP, in human 
skin mast cells25,26. MRGPRX2 or MRGPRB2-mediated activation of mast cells can result 
in a remarkably fast degranulation dynamics, which is associated with the development of 
rapid and localized mast cell-dependent inflammation25.
Whether specialized neuro-immune cross-talk has a role in the development of allergic skin 
inflammation remains unclear. Combining genetically-modified mouse models with 
intravital imaging approaches, we show here that a large proportion of TRPV1+ nociceptor 
projections form physical contacts with MRGPRB2+ mast cells. These neuro-immune 
clusters can sense the presence of allergic cues and can trigger pathogenic type 2 immune 
responses and associated lesions in the skin.
Results
Tac1 expression is required for allergic skin inflammation
We used a mouse model of allergic skin inflammation driven by six epicutaneous exposures 
over one month to two antigens found together in the lesional skin of 80-100% of AD 
patients2–7,26, 10 μg of the HDM strain Dermatophagoides farinae (D. farinae) and 500 ng of 
the bacterial exotoxin SEB from S. aureus (Supplementary Fig. 1a,b). Compared to healthy 
subjects, AD patients often suffer from S. aureus skin infections which are thought to play 
an important role in the pathogenesis and/or worsening of AD6. This model recapitulates 
moderate to severe AD-like disease, associated with both the histopathological features of an 
exacerbated type 2 immune response and a global gene expression pattern statistically 
similar to that seen in human AD8,27. Wild-type mice sensitized with a combination of SEB 
and D. farinae developed more severe skin inflammation than those treated with SEB or D. 
farinae alone, while D. farinae alone induced more skin lesions than SEB alone 
(Supplementary Fig. 1c,d). Compared to vehicle, treatment with D. farinae + SEB induced a 
systemic D. farinae-specific TH2 response (Supplementary Fig. 1e,f). In accord with reports 
that patients with moderate to severe AD were treated successfully with dupilumab28, a 
human monoclonal antibody against the IL-4 receptor α (IL-4Rα) that inhibits both IL-4 
and IL-13 signaling, systemic treatment with blocking antibodies for the mouse IL-4Rα 
significantly decreased the skin lesions and the histopathological features in the AD-like 
mouse model (Supplementary Fig. 1g,h). These data indicate that treatment with D. farinae 
Serhan et al. Page 3
Nat Immunol. Author manuscript; available in PMC 2020 April 07.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
+ SEB leads to the development of AD-like allergic skin inflammation dependent on type 2 
cytokines.
The neuropeptide SP is thought to be released primarily from a unique subpopulation of 
TRPV1+ TRPA1- peptidergic nociceptors that highly express Tac129, the gene encoding the 
SP precursor. Using publicly available gene expression data30, we mapped the expression of 
Trpv1, Tac1 and Trpa1 among different mouse tissues and various subpopulations of 
immune cells. Trpv1, Tac1 and Trpa1 were highly (or exclusively, in the case of Trpv1 and 
Trpa1) expressed in dorsal root ganglia (DRG), where the somas of sensory neurons are 
located, with weak additional expression of Tac1 in the central and the enteric nervous 
systems (Fig. 1a and Supplementary Fig. 1i). In whole-mounted skin biopsies from 
C57BL/6J wild-type mice, SP expression was restricted to PGP9.5+cutaneous neuronal 
fibers (Fig. 1b).
To analyze the role of SP in the development of allergic skin inflammation, we treated wild-
type and Tac1-/- mice with D. farinae + SEB and assessed the development of key 
pathological features associated with AD8. Compared to vehicle-treated wild-type mice, D. 
farinae + SEB-treated wild-type mice developed macroscopic skin lesions (Fig. 1d), 
increased epidermal thickness, strong infiltration of eosinophils and neutrophils (Fig. 1e) 
and elevated serum D. farinae-specific IgG1 and IgE (Fig. 1f), along with a profound 
alteration of filaggrin protein expression (Fig. 1g,h), a key component of skin barrier 
function linked to human AD12. In addition, D. farinae + SEB-treated wild-type mice had 
increased expression of keratin 6 (K6), a marker of inflammatory stress in keratinocytes 
(Supplementary Fig. 2a,b) and alterations in claudin-1, K14 and K10 expression 
(Supplementary Fig. 2c-h). Expressions of two other structural proteins loricrin and E-
cadherin were not significantly affected (Supplementary Fig. 2i-l). By contrast, D. farinae + 
SEB-treated Tac1-/- mice were mostly protected from disease, with substantial reduction in 
skin lesion development, histological abnormalities, infiltration of immune cells, serum 
levels of D. farinae-specific IgG1 and IgE and changes in skin barrier architecture (Fig. 1c-h 
and Supplementary Fig. 2). Taken together, this data suggested that expression of Tac1 and 
SP was restricted to the neuronal compartment of the skin and that expression of Tac1 was 
required for the full development of the pathological features associated with allergic skin 
inflammation in this model.
HDMs directly activate substance P-producing TRPV1+ neurons
To analyze the role of TRPV1+ nociceptors in the development of allergic skin 
inflammation, we treated wild-type mice systemically with resiniferatoxin (RTX), which is a 
potent TRPV1 agonist selectively ablating TRPV1+ nociceptors17,18 (Supplementary Fig. 
3a,b). RTX-treated mice and control DMSO-treated mice were subsequently treated with D. 
farinae + SEB to induce allergic skin inflammation. RTX-treated mice had a strong 
reduction of skin lesions (Fig. 2a,b) and lesion-associated histopathological features 
compared to control DMSO-treated mice (Fig. 2c), along with restored filaggrin 
organization and decreased expression of the stress marker K6 (Supplementary Fig. 3), 
suggesting that TRPV1+ nociceptors were required for the full development of allergic skin 
inflammation in this model.
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The primary function of nociceptors is to detect potentially damaging stimuli and initiate 
appropriate behavioral responses such as removal or scratching. We investigated whether D. 
farinae and SEB were directly detected by TRPV1+ DRG neurons cultured ex vivo. We 
found that 5 ng/ml SEB alone induced only a weak (barely detectable in some experiments) 
influx of calcium in DRG neurons (Fig. 2d,e), while concentrations ranging from 5 ng/ml of 
D. farinae, either alone (Fig. 2d,f) or in combination with 5 ng/ml SEB (Fig. 2d,g) triggered 
an increase in intracellular calcium in a subpopulation of DRG neurons that also responded 
to the TRPV1 agonist capsaicin (Fig. 2h,i).
D. farinae alone or in combination with SEB also triggered the secretion of SP from DRG 
neurons, with a tendency, in some experiments, for D. farinae + SEB to trigger less secretion 
of SP compared to either alone (Fig. 2j). Moreover, cultured DRG neurons from RTX-
treated mice did not secrete SP in response to D. farinae alone or D. farinae + SEB, while 
DRG neurons from DMSO-treated mice secreted SP (Fig. 2k). Importantly, DRG neurons 
from RTX-treated mice were also unresponsive to capsaicin (Fig. 2k) indicating that in vivo 
RTX-treatment efficiently depleted TRPV1+ neurons. These data indicated that D. farinae 
directly triggered the secretion of SP from TRPV1+ DRG neurons cultured ex vivo.
Next, we investigated by which mechanism D. farinae activated TRPV1+ DRG neurons. 
Treatment of DRG neurons with NBP2-29328, a MYD88 inhibitory peptide8, did not 
prevent D. farinae-induced activation of DRG neurons compared to DRG neurons treated 
with a non-relevant control peptide (Supplementary Fig. 4a,b), indicating that, at least under 
the culture conditions used here, DRG neurons activation was not dependent on MYD88-
dependent signaling through Toll like receptors (TLR). Next, we investigated whether the 
proteolytic activity of D. farinae was required for triggering DRG neuron activation ex vivo. 
Like other common environmental allergens, HDM strains, including D. farinae31 have 
intrinsic proteolytic activity that can degrade epithelial junctions32–35 or full-length IL-3336 
in vivo. To characterize the type of proteolytic activity present in the D. farinae extracts 
used, we measured the proteolytic activities of D. farinae with or without specific and 
irreversible inhibitors of cysteine or serine protease activities. Pretreatment with the cysteine 
protease inhibitor E64, but not with the serine protease inhibitor AEBSF, completely 
inhibited the proteolytic activity of D. farinae, at levels comparable to heat-inactivation of D. 
farinae (Fig. 3a). No proteolytic activity was measured in the absence of dithiothreitol 
(DTT), a reducing agent required for cysteine protease activity in cell-free conditions (Fig. 
3a), indicating the presence of cysteine protease activities in the D. farinae extract. SEB 
alone neither exhibited protease-like activity nor enhanced D. farinae proteolytic activity 
(Supplementary Fig. 4c).
Heat-induced inactivation or treatment with E64 prevented the influx of calcium in TRPV1+ 
DRG neurons by D. farinae ex vivo (Fig. 3b-e). However, TRPV1+ DRG neurons activation 
was independent of the expression of the protease-activated receptor PAR2 by the neurons 
(Supplementary Fig. 4a,b). We next investigated whether other clinically-relevant 
environmental allergens with either predominant cysteine protease activity, such as the HDM 
strain D. pteronyssinus31 or serine-like protease activities36 from pollen (ragweed), fungus 
(Alternaria alternata) or the German cockroach could also directly activate DRG neurons. 
Only D. pteronyssinus triggered significant influx of calcium in DRG neurons, comparable 
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to those obtained after stimulation with D. farinae (Fig. 3f). These data indicate that two 
common HDM strains with predominant cysteine protease activity involved in allergic 
inflammation and suspected to have major roles in various allergic disorders, could trigger 
the activation of a subset of nociceptors directly, predominantly via a cysteine protease 
activity-dependent mechanism.
Functional MRGPRB2 is required for allergic skin inflammation
Mouse MRGPRB2 and its human ortholog, MRGPRX2 are mast cell-restricted receptors for 
several cationic substances, including the neuropeptide SP. We used Kit-dependent 
KitW-sh/W-sh mast cell-deficient mice, in which KIT, the receptor for the main mast cell 
growth and survival factor SCF is mutated, and Kit-independent Cpa3-Cre+Mcl-1fl/fl mast 
cell-deficient mice, in which the antiapoptotic factor Mcl-1 is deleted in the mast cell lineage 
(Supplementary Fig. 5 and Supplementary Fig 6a-d) to study the role of mast cells in the 
development of allergic skin inflammation. After treatment with D. farinae + SEB, both 
KitW-sh/W-sh and Cpa3-Cre+Mcl-1fl/fl mice had a marked reduction in skin lesions compared 
to Kit+/+ and Cpa3-Cre-Mcl-1fl/fl littermate controls, respectively (Supplementary Fig. 5). 
Importantly, Tac1-/- mice or RTX-treated wild-type mice had normal numbers of dermal 
mast cells (Supplementary Fig. 6e,f), indicating that the reduced pathological features in 
these mice after treatment with D. farinae + SEB could not be attributed simply to a lack or 
reduction in the number of skin mast cells.
To assess whether MRGPRB2 contributed to the development of allergic skin inflammation, 
we used Mrgprb2mut/mut mice, in which MRGPRB2 is genetically inactivated by mutation, 
but have normal numbers of mast cells24 (Supplementary Fig. 6g,h). In contrast to 
Mrgprb2+/+littermates, Mrgprb2mut/mut mice did not develop allergic skin inflammation after 
treatment with D. farinae + SEB, and had substantial reductions in skin lesions (Fig. 4a,b), 
histological abnormalities, infiltration of eosinophils and neutrophils (Fig. 4c), D. farinae-
specific IgE (Fig. 4d) and disruption of skin barrier architecture (Fig. 4e,f and 
Supplementary Fig. 7), suggesting that MRGPRB2 expressed on mast cells contributed to 
the development of this model of allergic skin inflammation induced by D. farinae + SEB.
TRPV1+ nociceptors activate skin mast cells through MRGPRB2
We next explored whether D. farinae and SEB triggered the degranulation of dermal mast 
cells in vivo through the activation of TRPV1+Tac1+ nociceptors and MRGPRB2. A single 
intradermal (i.d.) injection of sulforhodamine 101-labeled avidin (Av-SRho) can be used to 
monitor skin mast cell granule structures specifically in live mice by two-photon microscopy 
or ex vivo by confocal microscopy37. We injected vehicle or 1 μg D. farinae + 50 ng SEB 
i.d. into the ear pinna of Av.SRho-injected mice and measured tissue swelling, as an early 
readout of inflammation and Av.SRho+ mast cell degranulation in whole-mounted ear skin 
using ex vivo volumetric confocal microscopy 45 minutes post D. farinae + SEB injection 
(Supplementary Fig. 8a). I.d. injection of vehicle induced very mild swelling of the ear 
tissue (Fig. 5a) and did not trigger substantial skin mast cell degranulation (Fig. 5b,c) in 
DMSO-treated wild-type mice or Mrgprb2+/+ mice, while injection of D. farinae + SEB 
induced strong ear swelling (Fig. 5a) and abundant degranulation of Av.SRho+ mast cells 
(Fig. 5b,d). After injection of D. farinae + SEB, RTX-treated wild-type mice or 
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Mrgprb2mut/mut mice had a substantial reduction of both ear swelling (Fig. 5a) and 
degranulation of Av.SRho+ mast cells (Fig. 5b,d) compared to DMSO-treated wild-type or 
Mrgprb2+/+ mice. Wild-type mice injected i.d. with blocking antibodies against SP had a 
strong reduction of both ear swelling (Fig. 5e) and mast cell degranulation (Fig. 5f,g) 
compared to IgG isotype-treated control mice. In addition, a 30 minute pretreatment of D. 
farinae + SEB with the cysteine protease inhibitor E64 decreased ear swelling significantly 
(Supplementary Fig. 8b,c). D. farinae and/or SEB did not trigger the degranulation of in 
vitro-cultured mouse or human mast cells at the tested concentrations (Supplementary Fig. 
8d,e).
We next tested whether activation of TRPV1+ nociceptors in the skin using the TRPV1 
agonist capsaicin would result in MRGPRB2-dependent mast cell degranulation in vivo. I.d. 
injection of 1 μM capsaicin did not induce significant ear tissue swelling (Fig. 5h) or 
Av.SRho+ mast cell degranulation (Fig. 5i,j) in RTX-treated wild-type mice or 
Mrgprb2mut/mut mice, while strong ear swelling (Fig. 5h) and linked degranulation of 
Av.SRho+ mast cells (Fig. 5i,j) were observed in DMSO-treated wild-type and 
Mrgprb2+/+mice, indicating that the effect was largely dependent on TRPV1+ nociceptors 
and MRGPRB2. These results indicate that, upon i.d. injection of D. farinae + SEB or 
capsaicin, the observed mast cell degranulation and associated early signs of inflammation 
require functional TRPV1+ nociceptors, release of SP and signaling through MRGPRB2.
Next, we adapted the fluorescent avidin-based mast cell imaging approach to visualize the 
activation of TRPV1+ nociceptors and the activation of mast cells simultaneously using 
intravital two-photon microscopy37. For this purpose we used Pirt-GCaMP3 mice, in which 
expression of the calcium tracer GCaMP3 is driven by the Pirt promoter in sensory 
neurons38 in order to track the spatiotemporal dynamics of skin mast cell granule structures 
and TRPV1+ nociceptors activation in living mice (Supplementary Fig. 8f). Low basal 
expression of GCaMP3 fluorescence (Fig. 6a,b and Supplementary Fig. 8g) in sensory 
neurons, but no degranulation of Av.SRho+ mast cells (Fig. 6a,c and Supplementary Fig. 8h) 
were detected after i.d. injection of vehicle. In contrast, i.d. injection of 1 μM of the TRPV1 
agonist capsaicin induced strong increases in GCaMP3 fluorescence (Fig. 6a,b and 
Supplementary Fig. 8g), revealing the presence of an abundant network of activated 
TRPV1+ nociceptors in the mouse dermis, as well as degranulation of ~50-60 % of Av.SRho
+
 mast cells (Fig. 6a,c and Supplementary Fig. 8h). After i.d. infusion of 1 μg D. farinae + 50 
ng SEB, either in combination or separately, in Av.SRho-labelled Pirt-GCaMP3 mice we 
observed a significant increase in GCaMP3 fluorescence in skin neurons compared to 
vehicle-injected mice (Fig. 6a,b) and degranulation of ~ 50% Av.SRho+ mast cells (Fig. 
6a,c), suggesting that the presence of D. farinae and/or SEB antigens in the dermis could 
lead to the activation of TRPV1+ nociceptors and mast cells in vivo. Finally, we used an 
automated computer-assisted calculation method to perform an unbiased analysis of the 
spatial organization of activated TRPV1+ nociceptors and Av.SRho+ mast cells in the dermis 
of Pirt-GCaMP3 mice as assessed by live imaging. About 62 % of Av.SRho+ mast cells 
either formed contacts with activated TRPV1+ nociceptors in the skin (25%) or resided in 
close proximity to activated nociceptors (37% of Av.SRho+ mast cells were within less than 
25 μm from activated TRPV1+ nociceptors) (Fig. 6d-f). These data suggest that mast cells 
and TRPV1+ nociceptors formed cellular clusters in the skin that can be activated in the 
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presence of D. farinae and SEB. Together, these results indicated that the ear swelling 
observed upon i.d. injection of D. farinae + SEB resulted from the activation of skin 
TRPV1+ nociceptors which induced the degranulation of mast cells through the release of 
SP and the activation of MRGPRB2.
Discussion
Here we found that TRPV1+Tac1+ nociceptors and MRGPRB2+ mast cells formed clusters 
in the mouse skin that could be activated by allergens, such as HDMs. This, in turn, drove 
the development of type 2 immunity-associated skin inflammation in mice that mimicked 
many features of human AD. In addition, our results identified MRGPRB2 as a key receptor 
that facilitated communication between skin mast cells and TRPV1+Tac1+ nociceptors.
Based on the generated high-resolution 3D images, it is interesting to speculate that the close 
anatomical co-localization of mast cells and TRPV1+ nociceptors in the mouse dermis might 
enable the accumulation of high enough amounts of secreted neuropeptide such as SP to 
reach the previously reported high activation threshold of MRGPRB239. Fixed biopsies have 
indicated proximity or contact between nerve fibers and mast cells in mice, pigs and 
humans40–43, while mouse and human mast cells can be directly activated by neuropeptides 
(including SP) in vitro25,42,44. A bi-directional activation process between mast cells and 
submucosal neurons in cultured gut biopsies has been reported45. Our study offers direct 
evidence of functional interactions between nociceptors and mast cells in vivo and identified 
these interactions as a critical element in the development of type 2 skin inflammation. 
Targeting SP-enabled interactions between TRPV1+ nociceptors and MRGPRX2+ mast cells 
might therefore represent a promising therapeutic approach for the prevention and/or 
treatment of human AD pathology.
Recent studies have reported that MRGPRB2 on mast cells has an important role in the 
regulation of inflammatory pain46 and itch sensation47. SP and MRGPRB2 were reported to 
be directly involved in the regulation of inflammatory mechanical and thermal hyperalgesia, 
and in the recruitment of innate immune cells at the site of injury46. In addition, compared to 
activation through canonical FcεRI, mast cell activation through MRGPRB2 induces itch 
distinct from classical histaminergic itch47. MRGPRB2-mediated activation of mast cells 
results in the differential release of granule-associated mediators (including some with 
known pruritogen function such as histamine, serotonin or tryptase), and MRGPRB2 
deficiency significantly decreases itch in different models of allergic contact dermatitis, 
which is thought to be associated with pathogenic CD8+ T cell responses48. These 
observations indicate that MRGPRB2 activation on mast cells modulates the transmission of 
sensations of pain and itch in different inflammatory contexts.
Mast cells can drive certain types of IgE-independent pseudo-allergic reactions through the 
binding of a wide range of cationic drugs (such as the FDA-approved mivacurium or 
icatibant) to MRGPRX2 or MRGPRB224,49,50. It is tempting to speculate that MRGPRX2 
or MRGPRB2-mediated mast cell activation by cationic drugs could lead to the activation of 
nociceptors at the site of injection and the subsequent development of pain and/or itch. 
However, more in vivo work is needed to define whether the clusters of TRPV1+Tac1+ 
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nociceptors and MRGPRB2+ mast cells described here are involved in drug-induced adverse 
events.
We found that D. farinae, but not SEB, directly activated TRPV1+ DRG neurons ex vivo 
through a cysteine protease-dependent mechanism. We can’t rule out the possibility that 
direct effects of D. farinae and/or SEB on skin mast cells, apart from effects on 
degranulation, also may have contributed to our findings. However, the data presented 
suggest that, under the conditions studied, D. farinae + SEB-induced cutaneous 
inflammation required TRPV1+ nociceptors and the release of SP, which then activated skin 
mast cells.
Most patients with severe AD are colonized with exotoxin-producing S. aureus4,6,7. In 
agreement to that, we found that D. farinae in combination with SEB triggered the 
development of more severe skin inflammation than when the two antigens were used 
separately. While SEB alone did not activate DRG neurons cultured ex vivo, after i.d. 
injection in vivo it triggered GCaMP3 fluorescence in skin neurons comparable to that 
observed after injection of D. farinae. This might indicate that SEB activated nociceptors 
through an indirect mechanism; however, the precise mechanism(s) remain(s) to be 
elucidated. It is possible that SEB, which is known to be a potent superantigen, could also 
favor the proliferation of T cells in our model. However, SEB treatment alone in wild-type 
mice triggered less severe skin inflammation and skin lesions than treatment with D. farinae 
alone. It is therefore possible that a direct mechanism of nociceptor activation by D. farinae 
cysteine protease activity might be required to efficiently trigger the development of this 
model of D. farinae + SEB-induced allergic skin inflammation.
The sensing of allergen-associated proteolytic activity has been proposed to be an important 
mechanism of environmental allergen detection that could contribute to the initiation of 
allergic diseases31,36. Our data suggest that the clusters of TRPV1+ nociceptors and 
MRGPRB2+ mast cells might represent tissue-resident “sensory systems” that would detect 
allergens with cysteine-like protease activity in the skin and initiate type 2 immunity-
associated allergic skin disease. Sensory nerve fibers and mast cells are also present in the 
upper airways, lungs and gastro-intestinal tract, which are organs continuously exposed to 
environmental allergens and within which allergic diseases are also known to develop. 
However, the extent to which neuron-mast cell clusters are involved in the development of 
other allergic disorders in different organs remains to be investigated.
Methods
Mice
Four- to 8-week-old C57BL/6J and Tac1-/- mice were purchased from Charles River or the 
Jackson Laboratory; both age-matched male and female mice were used in experiments. 
Mrgprb2mut/mut mice (which are homozygous for a mutation that induces a genetic 
inactivation of Mrgprb224) and Pirt-GCaMP3 mice (in which a genetically encoded calcium 
tracer [GCaMP3] is driven into sensory neurons by the Pirt promoter38) were provided by X. 
Dong and both male and female mice were used in experiments. The mast cell-deficient 
KitW-sh/W-sh and Cpa3-cre+;Mcl-1fl/fl mice have been described previously25,37; both male 
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and female mice were used in experiments. PAR-2-deficient mice were a generous gift from 
N. Vergnolle. Mice were bred and housed in the local animal facilities of CREFRE 
(Toulouse, France) or Stanford University (CA, USA), and littermate control mice were used 
in all experiments. All animal care and experimentation were conducted in France and in the 
USA. Experiments conducted in USA (Galli Lab, Stanford University, CA) were in 
compliance with the guidelines of the National Institutes of Health (NIH) and the 
Institutional Animal Care and Use Committee of Stanford University. Experiments 
conducted in France (Gaudenzio Lab, INSERM, University of Toulouse) were in compliance 
with the guidelines of the European Union (86/609/EEC) and the French Committee of 
Ethics (87/848) policies and with the specific approval from the local ministry-approved 
committee on ethics in animal experimentation (Ethics Committee UMS006 CEEA-122, 
project n° 13283 2018031416055447V3). 8 to 12-week-old mice were used in experiments, 
excepted for RTX treatment for which 4-week-old mice were used.
Reagents and antibodies
Sodium citrate, Bovine Serum Albumin (BSA), DMSO, saponin, Capsaicin, Resiniferatoxin 
and Staphylococcal Enterotoxin B (SEB) were from Sigma-Aldrich. HDM extracts of the 
strain Dermatophagoides farinae were purchased from Greer Laboratories. The following 
antibodies were obtained from Covance: anti-Keratin (K) 14, anti-K6, anti-K10, anti-loricrin 
and anti-filaggrin. Anti-Claudin 1 was from Abcam. Alexa594-conjugated goat anti-rabbit 
IgG, Alexa488-conjugated avidin and DAPI were from Life Technologies Invitrogen. The 
following reagent and antibodies were from eBioscience Thermofisher Scientific: 
CellTrace™ CFSE Cell Proliferation Kit, anti-CD4-APC, anti-IL4-PE, anti-IL-5-PE, anti-
IL-13-PE, and anti-IFNγ-PE. Purified NA/LE Rat Anti-Mouse CD124 (mIL4R-M1) or 
control Istoype (R35-95) were from BD Bioscience. MYD88 inhibitory peptide (i.e., a cell 
permeant peptide sequence that selectively blocks MYD88 homodimerization) and a control 
peptide (i.e., an inactive and cell permeant truncated form of the MYD88 inhibitory peptide) 
were from Novus. Alternaria alternata (A. alternata), Dermatophagoides pteronyssinus (D. 
pteronyssinus), ragweed and German Coackroach were all from Stallergenes Greer.
Model of allergic skin inflammation
Allergic skin inflammation was induced as previously described8,27 (described in 
Supplementary Fig. 1). Briefly, back skin was shaved and a solution of 500 ng of 
Staphylococcal enterotoxin B (SEB, Sigma-Aldrich) and of 10 μg of Dermatophagoides 
farinae extract (HDM, Stallergen Greer) in PBS was applied on a gauze pad placed on the 
shaved back and occluded with a Tegaderm™ Transparent Dressing (3M HealthCare). Three 
days later, the gauze pads were replaced. Mice were monitored on a daily basis and if a 
mouse removed the bandage, a new dressing was immediately applied on this mouse and all 
of the other mice within the same experiment (so that they received the same treatment and 
equal amounts of antigens). Four days later, dressings were removed and mice were kept 
without treatment for the next week. This "3 + 4 days” pattern of treatment was repeated two 
more times, so that the mice were subjected to three cycles of such treatment. Two days after 
the last cycle of treatment, the mice were euthanized and back skin specimens corresponding 
to the treated areas were obtained for analyses. In a set of experiments, mice were also 
treated with either IgG isotype control or anti-CD124 antibody (100 μL; i.p.) at 2.8 mg/kg 
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twice a week for the entire period of treatment. The last treatment with either of these 
antibodies was done one day before sacrifice. This model has been efficiently used in both 
Inserm Toulouse and Stanford University and key experiments have been repeated in both 
animal facilities.
Ablation of Trpv1+ nociceptors in mice
To ablate Trpv1+ nociceptors, 4-week-old C57BL/6J mice were subcutaneously injected 
with increasing resiniferatoxin (RTX) doses of 30 μg/kg, 70 μg/kg and 100 μg/kg in 100 μL 
of PBS for 3 consecutive days. Control mice were injected with similar volumes of DMSO 
in 100 μL of PBS. 4 weeks later, denervation was assessed using the classical tail flick assay.
Peripheral blood mononuclear cell-derived human mast cell culture
Peripheral blood mononuclear cells were obtained from buffy coats of healthy blood donors 
at the Etablissement Francais du Sang (EFS) and were cultured as described in Gaudenzio et 
al.25. Briefly, isolated CD34+ cells (EasySep Human CD34 Positive Selection Kit, 
STEMCELL Technologies) were cultured for one to two weeks in StemSpan medium 
(STEMCELL Technologies) supplemented with recombinant human IL-6 (50 ng/ml; 
Peprotech), human IL-3 (10 ng/ml; Peprotech), ciprofloxacin (10 μg/ml; Sigma-Aldrich) and 
3% supernatant of CHO transfectants secreting mouse SCF. After two weeks, cells were 
transferred to IMDM Glutamax supplemented with sodium pyruvate, 2-β-mercaptoethanol 
(50 μM), 0.5% BSA, 1% insulin transferrin selenium (all from Invitrogen), ciprofloxacin (10 
μg/ml; Sigma-Aldrich), IL-6 (50 ng/ml) and 3% supernatant of Chinese hamster ovary 
(CHO) transfectants secreting mouse SCF. Mast cells were usually ready for experiments 
after ~10 weeks in culture.
Bone marrow-derived cultured mouse mast cells (BMCMCs)
Hematopoietic cells were collected from C57BL/6 mouse femurs and cultured in DMEM 
supplemented with L-Glutamax, 2-β-mercaptoethanol (50 μM; Invitrogen), murine IL-3 (10 
ng/mL; Peprotech), 10% Fetal Bovine Serum (FBS, Invitrogen) and Peni/Strep (100X). 
Twenty-four hours later, adherent cells were removed, and fresh culture medium was added 
to non-adherent cells. Three days later, cells were resuspended in fresh culture medium. The 
same procedure was repeated twice a week. Cells were used for experiments between week 
4 and week 10.
β-Hexosaminidase release assay
Human mast cells were incubated in culture medium with or without human IgE (1 μg/mL; 
Sigma-Aldrich) overnight at 37°C. BMCMCs were incubated with or without anti-
dinitrophenol (DNP) IgE (0.5 μg/mL; Sigma Aldrich) overnight at 37°C. The cells were then 
washed and distributed in 96-well flat-bottom plates at a density of 105 cells in 50 μL of 
Tyrode’s buffer at 37°C. 40 minutes later, cells were treated with 50 μL of prewarmed 
stimuli diluted in Tyrode’s buffer for 45 minutes at 37°C. As a positive control of functional 
activation, human mast cells were stimulated with anti-IgE (10 ng/mL; Euromedex) and 
BMCMCs with DNP-BSA (10 ng/mL; Sigma Aldrich). To assess whether AD antigens 
could activate mast cells, human mast cells and BMCMCs were stimulated with increasing 
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concentrations of D. farinae and SEB (5 ng/mL, 50 ng/mL and 500 ng/mL), alone or 
together. β-Hexosaminidase release in the supernatants was measured as previously 
described25.
Intracellular flow cytometry of D. farinae-specific CD4+ T cells
Following induction of allergic skin inflammation, spleens from vehicle-treated or D. farinae 
+ SEB-treated mice were harvested and dissociated to obtain a suspension of cells. 200,000 
spleen cells were stained with CFSE for 7 minutes at 37°C and incubated for 5 days with 10 
μg/ml of D. farinae in RPMI 1640 supplemented with 10% FCS GlutaMAX-I, sodium 
pyruvate, 2-mercaptoethanol, and 10μg/ml ciprofloxacin. Intracellular cytokines were 
analyzed by gating on proliferating (CFSElow) CD4+ T cells after a 5-hour restimulation 
with phorbol 12-myristate 13-acetate (50 ng/mL, Sigma) and ionomycin (1 mg/mL, Sigma) 
in the presence of GolgiStop (BD Pharmingen). Cells were fixed, permeabilized (0.1% 
saponin in PBS 0.5% BSA), and stained with antibodies directed against mouse IL-4, IL-5, 
IL-13 or IFN-γ. Flow cytometric data were acquired on a BD FACSCanto cytometer and 
were analyzed using FlowJo software (Tree Star, Inc, Ashland, Ore).
Skin section preparation, histology, immunofluorescence, and confocal microscopy
Mouse back skin (1-2 cm2) samples were fixed in 10% formalin and embedded in paraffin. 
Four-micrometer-thick sections were stained with H&E, and photographs were taken using a 
Nikon H600L microscope and analyzed with NIS-Elements imaging Software. All sections 
were “coded” so the evaluator was not aware of their identity, as previously described8. 
Eosinophils and neutrophils were counted on H&E-stained skin sections from all mouse 
strains. For immunostaining of mouse specimens, 4-μm-thick sections were pretreated using 
a heat-induced epitope retrieval method8 in 10 mM sodium citrate buffer (pH 6.0), then 
permeabilized for 30 minutes in PBS supplemented with 0.5% BSA and 0.1% saponin. 
Permeabilized skin sections were incubated overnight at 4°C with primary antibodies, 
extensively washed, and incubated with appropriate secondary antibodies for 2 hours at 
room temperature in the dark. Images of 1024 x 1024 pixels were acquired using a Zeiss 
LSM780 and LSM710 Meta inverted confocal laser-scanning microscopes. Images were 
processed using Zen software (Zeiss). Epidermal K6, K17, Claudin 1, Filaggrin, Loricrin 
and E-cadherin mean fluorescence intensities were analyzed using the "measurement 
function" of ImageJ software on randomly chosen epidermal areas of identical size (i.e., 
same total number of pixels).
Amounts of serum D. farinae-specific IgG1 and IgE antibodies by ELISA
Each incubation step described below was followed by 3 to 5 washing steps using PBS 
containing 0.05% Tween-20. MaxiSorp ELISA plates (Nunc) were coated with 5 μg/ml D. 
farinae at 4°C overnight. Plates were then blocked with 1% Bovine Serum Albumin (BSA) 
in PBS for at least 2 hours at room temperature. Sera diluted in PBS containing 1% BSA 
were added and incubated in the blocked wells for 2 hours at 37°C. Afterwards, biotinylated 
detection antibodies (rat anti-mouse IgG1 and rat anti-mouse IgE; BD Biosciences; 1:1000) 
were then added for 1 hour at room temperature followed by incubation with horseradish 
peroxidase-conjugated streptavidin (BD Biosciences; 1:2000) for 30 minutes at room 
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temperature. Reaction was then revealed using supersensitive 3,3’,5,5’-tetramethylbenzidine 
(TMB; Sigma Aldrich) substrate and OD was measured at 450 nm.
D. farinae proteolytic activity assay
D. farinae samples were diluted to 200 μg/mL in a reaction buffer composed of Sodium 
Phosphate 100 mM pH 6, EDTA 10 mM, and DTT 1 mM. The extract was incubated or not 
with irreversible protease inhibitors (cysteine protease inhibitor E64 100 nM or serine 
protease inhibitor AEBSF 1 mM) in a reaction volume of 50 μL. Activity was measured 
using Boc-Gln-Ala-Arg-AMC fluorogenic substrate (200 μM, diluted in the same reaction 
buffer). D. farinae extracts and substrate solutions were incubated separately for 20 minutes 
at 37°C. Immediately after addition of 50 μL substrate solution on the D. farinae extracts, 
the release of AMC fluorescence was followed over time using a varioskan Flash apparatus 
(Thermo Scientific). The initial velocity reflecting proteolytic activity was calculated from 
the kinetics curves. A control was performed by heat-inactivating D. farinae extract for 60 
minutes at 95°C before addition of substrate. An additional control was performed in a 
reaction buffer devoid of DTT.
Dorsal Root Ganglia (DRG) dissociation, culture, and Ca2+ imaging
DRG neurons from all spinal levels were collected in ice-cold Dulbecco’s modified Eagle’s 
medium (DMEM)/F-12 supplemented with 10% FBS, penicillin (100 U/mL), and 
streptomycin (100 μg/mL). DRGs were digested with a mixture of dispase (5 mg/ml) and 
collagenase type I (1 mg/ml) enzyme at 37°C for 45 minutes. After dissociation, cells were 
spun at 300g and re-suspended in media before being plated on glass coverslips coated with 
poly-D-lysine (0.5 mg/ml) and laminin (10 μg/ml, Invitrogen) or Lab-tek II chambers slide 
with cover (Thermo Fisher Scientific). DRGs were cultured in media supplemented with 50 
ng/mL NGF at 37°C overnight (12-24 hours) before experimentation. In some experiments, 
control peptide, or MyD88 inhibitory peptide (100 μM), were added to the DRG cultures for 
16 h. Cells were imaged in calcium imaging buffer (CIB; 10 mM HEPES, 1.2 mM NaHCO3, 
130 mM NaCl, 3 mM KCl, 2.5 mM CaCl2, 0.6 mM MgCl2, 20 mM glucose, and 20 mM 
sucrose at pH 7.4 and 290-300 mOsm) or HBSS. To monitor changes in intracellular [Ca2+] 
([Ca2+]i), cells were loaded with Fura2-AM or Fluo-4 for 30 minutes in the dark at 37°C in 
CIB or Hepes /HBSS just prior to imaging. Emission at 520 nm was monitored after 
excitation at 340 nm (Ca2+ bound) or 380 (unbound). Cells were imaged for 20 seconds to 
establish a baseline before compounds were added. DRG were stimulated with 5 ng/ml D. 
farinae, 5 ng/ml heat-treated D. farinae (95°C for 60 minutes), 5 ng/ml D. farinae treated 
with 2.5 pM E64, 37°C for 30 minutes), 5 ng/ml SEB or 1 μM capsaicin. At the end of every 
imaging trial, 50 mM KCl was added as a positive control. Cells were identified as 
responding if the intracellular [Ca2+] rose by either 50% compared to baseline or 50% 
compared to the [Ca2+]i change assayed during addition of 50 mM KCl (neurons only). 
Damaged, detached, high-baseline and motion-activated cells were excluded from analyses. 
Those experiments were performed in the Dong Lab at Johns Hopkins University (and 
confirmed in the Gaudenzio Lab at INSERM, Toulouse France) in compliance with Johns 
Hopkins University ethical guidelines and Inserm Toulouse guidelines.
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Quantification of SP secretion
DRG of mice were cultured as described above, rinsed in Hanks Balanced Salt Solution 
(HBSS; Sigma), and incubated in L-cysteine containing 1% Papain (Sigma) for 10 minutes 
at 37°C. After a wash with filtered Leibovitz’s L-15 Medium (Gibco) containing 10% FBS 
(Sigma), they were incubated in HBSS containing collagenase (1 mg/ml; Sigma) and dispase 
(4 mg/ml, Sigma) at 37°C for 10 min. After titration, cells were plated in a Poly-D-lysine-
laminin (Sigma)-coated 12 well-plate (Corning) and recovered with the complete culture 
media (DMEM-Glutamax, 2.5% FBS, 1% pen/strep and ARAC, FUDR, uridine – 10 μM 
each; all from Sigma). Cells were incubated for 5 minutes with vehicle or 5 ng/ml D. farinae 
or 5 ng/ml SEB or and 125 nM capsaicin. Cell supernatants were tested with a Substance P 
Elisa kit (Enzo) following the manufacturer’s recommendations.
Ear pinna injection, mast cell staining, and ear thickness measurement
8 μg of Av.SRho in 20 μl of PBS were injected i.d. into both ear pinnae of WT, 
Mrgprb2mut/mut, and RTX-treated mice, and the respective Mrgprb2+/+ or DMSO-treated 
control mice, to selectively label mast cell secretory granules in vivo, as previously 
described37. 7 days later, ear thickness was measured and then right ear pinnae were injected 
i.d. with 1 μg D. farinae + 50 ng SEB (pre-incubated or not for 30 minutes at 37°C with 100 
nM of E64 cysteine protease inhibitor) or 1 μM capsaicin in 20 μl PBS. In some 
experiments, ear pinnae were injected i.d. with 1 μg D. farinae + 50 ng SEB with 15 μg of 
IgG anti-SP (Sigma Aldrich) in 20 μl PBS. Left ear pinnae were injected with 20 μL of 
respective control solutions: vehicle alone or in combination with IgG isotype control. 45 
minutes later, ear thickness was measured again and mice were euthanized before ear 
excision. Whole ears were fixed in 4% paraformaldehyde (PFA) overnight, then mounted on 
microscopy slides and placed under a LSM710 Meta inverted confocal laser-scanning 
microscope. High resolution Z-stack images 1024 x 1024 pixels of Av.SRho fluorescent 
signal were acquired using a 20x objective. Images were then processed using Image J and 
Imaris (Bitplane) softwares.
In vivo two-photon microscopy of living mice
Experiments were conducted as previously described25,37. Briefly, 8 μg of Av.SRho in 20 μl 
of PBS were injected i.d. into the ear pinna of Pirt-GCaMP3 mice. 1 week later, mice were 
injected i.d. with vehicle, 1 μM capsaicin, or 1 μg D. farinae and 50 ng SEB (used alone or 
in combination) in a final volume of 20 μl then placed under the two-photon microscope on 
a custom-built 3-D printed mouse platform; anesthesia was maintained by a mixture of 
Isoflurane/O2 and the animal’s ear pinna was kept at 36°C using a heating pad system. The 
fluorescence corresponding to Av.SRho+ mast cell granule structures or GCaMP3+ skin 
neurons was measured using a Prairie Ultima IV two-photon microscope (Spectra Physics 
Mai Tai HP Ti:sapphire laser, tunable from 690 to 1040 nm). Images were acquired in 3-D 
up to 100-150 μm depth, with 20x Olympus XLUM Plan Fl N.A. 0.95 water-immersion 
objective and a software zoom setting of 1 or 3 (8 bits/pixel 1024x1024, scaling x= 0.228 
μm, y= 0.228 μm, z= 0.5−μm). Modeling and analysis of fluorescent signals were performed 
using untreated image sequences, as previously described25, using Imaris software 
(Bitplane) and Image J software version Fiji, respectively.
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Automated computational analysis of the minimum distance between mast cells and 
neurons in the dermis of living mice
1) 3D high resolution images were taken using a Prairie Ultima IV two-photon microscope 
as described above. The following steps have been automated in the software Imaris 
Bitplane version 9.2. 2) Hair follicles’ autofluorescent signals were modeled into matched 
3D objects using the isosurface algorithm. 3) Autofluorescent signals corresponding to the 
generated isosurfaces were depleted from the GCaMP3 fluorescence detection channel so 
that the hair follicles were no longer detectable in that particular channel. 4) The filament 
tracer algorithm was applied in the GCaMP3 fluorescence detection channel in order to 
precisely trace the trajectories and exact shapes of GCaMP3 fluorescent signals. Filament 
traces were then converted into fluorescent signals in a new fluorescent channel. 5) Those 
newly generated fluorescent signals were modeled into matched 3D objects using the 
isosurface algorithm. The distance transformation algorithm was applied to those new 
isosurfaces resulting in the generation of a new distance transformation channel. 6) Av.SRho 
fluorescent signals were modeled into matched 3D objects using the isosurface algorithm. 
The intensity minimum (i.e., distance minimum in μm) to the distance transformation 
channel (i.e., modeled sensory neurons) was calculated for each of the Av.SRho+ isosurfaces 
of at least 5 μm of diameter (corresponding to Av.SRho+ mast cell cellular bodies and 
excluding small exteriorized Av.SRho+ granules structures). 7) Results per field of view 
were generated into separated Excel sheets. The exact same procedure was automatically 
applied to all analyzed 3D images.
Statistics
Statistical tests were performed with the software Prism 6 (GraphPad Software). Two-tailed 
unpaired/paired Student’s t tests, 1-way ANOVA with Tukey’s test for multiple comparisons 
or Holm-Sidak’s post-hoc test were performed on samples as noted in the respective figure 
legends. A P value of less than 0.05 was considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Tac1 gene expression is required for the full development of pathological features in a 
model of allergic skin inflammation.
a, Publicly available microarray gene expression data of Trpv1, Tac1 and Trpa1 in different 
mouse tissues (GSE 10246); data are shown using a heat map of mRNA expression levels. b, 
Representative 3D confocal microscopy picture of whole-mounted normal back skin stained 
for PGP9.5 (a pan neuronal marker, cyan) and substance P (red). c, Representative 
hematoxylin & eosin (H&E) staining of vehicle- or D. farinae + SEB-treated areas in WT or 
Tac1-/- mice. d, Clinical scores (0-12) of vehicle- or D. farinae + SEB-treated areas in WT or 
Tac1-/- mice treated as in c. e, Epidermal thickness (μm) (left), number of eosinophils 
(middle) and neutrophils (right) in skin sections in WT or Tac1-/- mice treated as in c. f, 
Serum levels (arbitrary unit [a.u]) of D. farinae-specific IgG1 (left) and IgE (right) 
antibodies in vehicle- or D. farinae + SEB-treated WT or Tac1-/- mice as in c. g,h, 
Representative confocal microscopy pictures of back skin sections (g) and fluorescence 
analysis (h) of filaggrin staining in the epidermis of vehicle- or D. farinae + SEB-treated 
areas in WT or Tac1-/- mice treated as in c. Bars = 100 μm, dotted black (c) or white (g) lines 
indicate the junction epidermis/dermis. Each circle = one mouse. Number of mice: (b) n = 3; 
(c-h) n = 6 (WT Vehicle), n = 14 (WT D. farinae + SEB), n = 7 (Tac1-/-). (e,f,h) Open bars: 
WT mice; black bars: Tac1-/- mice. (b-h) Data from three independent experiments, mean ± 
SEM (d), mean + SEM (e,f,h); 1-way ANOVA with Tukey’s test for multiple comparisons, 
*P<.05 **P<.01 ***P<.001.
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Figure 2. TRPV1+ nociceptors are required for the full development of allergic skin 
inflammation and D. farinae extracts directly induce neuronal activation.
a, Representative H&E staining of D. farinae + SEB-treated areas in mock 
(dimethylsulphoxide [DMSO])-treated or RTX-treated (TRPV1+ nociceptor ablated) mice. 
b, Clinical scores (0-12) of D. farinae + SEB-treated areas in DMSO- or RTX-treated mice 
as in a. c, Epidermal thickness (μm) (left), number of eosinophils (middle) and neutrophils 
(right) of D. farinae + SEB-treated areas in DMSO- or RTX-treated mice as in a. Number of 
mice: (a-c) n = 4 (DMSO) and n = 5 (RTX); data are from two independent experiments; 
mean + SEM, two-tailed, unpaired t-test, *P<.05 **P<.01 ***P<.001. d-h, Representative 
Fura-2 ratiometric fields (d), associated calcium traces (e-g) and (h) proportion of 
responding DRG neurons (%) of ex vivo cultured DRG neurons (expressed as % of DRG 
neurons responding to 50 mM KCL) stimulated with 5 ng/ml SEB (top d,e,h) or 5 ng/ml D. 
farinae (middle d,f,h) or both (bottom d,g,h) and 1 μM capsaicin (d-h). (d) Bars = 50 μm, 
white arrow heads indicate neurons with increased Fura-2 fluorescence. (d-h) Data are from 
three independent experiments performed with DRGs from n = 3 (for the condition of 
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vehicle-, D. farinae, SEB or D. farinae + SEB-treated DRG neurons) and n = 6 (for the 
condition of capsaicin-treated DRG neurons) different mice; mean + SEM, two-tailed, 
unpaired t-test, *P<.05 **P<.01. i, Venn diagrams of responding DRG neurons. j,k, 
Substance P secretion in DRG neurons cultured ex vivo from (j) WT mice, (k) DMSO (open 
bars)- versus RTX (black bars)-treated mice and stimulated as indicated. Data are from (j) 4 
and (k) 3 independent experiments, mean + SEM, two-tailed, unpaired t-test, *P<.05 **P<.
01 ***P<.001. Each circle = one mouse.
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Figure 3. Activation of DRG neurons by D. farinae extract depends on cysteine protease activity.
a, Protease activity in D. farinae extracts heat inactivated at 95°C for 60 minutes (Heated), or 
treated with cysteine- (E64, 100 nM) or serine- (AEBSF, 1 mM) protease inhibitors, with or 
without dithiothreitol (DTT). Data are from three independent experiments performed with 
three independent biological samples, mean + SEM, One way ANOVA and Holm-Sidak’s 
post- hoc test, *** P<.001. b-e, Representative Fura-2 ratiometric fields (b), associated 
calcium traces (c,d) and (e) proportion of responding DRG neurons (%) in ex vivo cultured 
DRG neurons (expressed as % of DRG neurons responding to 50 mM KCL) stimulated 
sequentially with 5 ng/ml heated D. farinae (top b,c) or 5 ng/ml E64 (2.5 pM)-treated D. 
farinae (bottom b,d), 5 ng/ml D. farinae and 50 mM KCL. Data are from five independent 
experiments performed with 22 (for the conditions Vehicle and D. farinae), 14 (for the 
condition Heated D. farinae) and 5 (for the condition E64-treated D. farinae) independent 
experiments performed with independent biological samples, mean + SEM, two-tailed, 
unpaired t-test, ***P<.001. f, Proportion of responding DRG neurons stimulated with either 
Vehicle, 5 ng/ml D. pteronyssinus, 5 ng/ml German cockroach, 5 ng/ml A. alternata, or 5 
ng/ml ragweed expressed as % of DRG neurons responding to 50 mM KCL. Data are from 
six independent experiments performed with six independent biological samples, mean + 
SEM, two-tailed, unpaired t-test, *P<.05. Each circle = one mouse.
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Figure 4. Genetic inactivation of MRGPRB2 largely prevents development of pathology in a 
model of allergic skin inflammation.
a, Representative H&E staining of D. farinae + SEB-treated areas in Mrgprb2mut/mut and 
Mrgprb2+/+ mice; dotted black lines indicate the junction epidermis/dermis. b, Clinical 
scores (0-12) of D. farinae + SEB-treated areas in Mrgprb2mut/mut and Mrgprb2+/+ mice as 
in a. c, Epidermal thickness (μm) (left), number of eosinophils (middle) and neutrophils 
(right) in D. farinae + SEB-treated areas in Mrgprb2mut/mut and Mrgprb2+/+ mice treated as 
in a. d, Serum levels (arbitrary unit [a.u]) of D. farinae-specific IgG1 (left) and IgE (right) 
antibodies of D. farinae + SEB-treated Mrgprb2mut/mut and Mrgprb2+/+ mice as in a. e,f, 
Representative confocal microscopy of back skin section (e) and fluorescence analysis (f) of 
filaggrin staining of D. farinae + SEB-treated areas in Mrgprb2mut/mut and Mrgprb2+/+ mice 
as in a. White lines indicate the junction epidermis/dermis. Bars = 100 μm. Each open circle 
= one mouse. Number of mice: (a-c,e,f) n = 6 (Mrgprb2+/+), n = 7 (Mrgprb2mut/mut); (d) n = 
5 (Mrgprb2+/+), n = 9 (Mrgprb2mut/mut). Mean ± SEM (b), mean + SEM (c,d,f), two-tailed, 
unpaired t-test, *P<.05 **P<.01 ***P<.001.
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Figure 5. Sensory neurons, MRGPRB2 and substance P are required to trigger in vivo mast cell 
degranulation and associated skin swelling in response to D. farinae and SEB antigens.
a, Changes (Δ) in ear thickness 45 minutes after i.d. injection of vehicle or D. farinae + SEB 
in DMSO-treated (open squares), RTX-treated (grey squares), Mrgprb2+/+ (open circles) or 
Mrgprb2mu/mut (grey circles) mice. b, 3D representative confocal microscopy pictures of 
Av.SRho fluorescent signal (red) in whole-mounted ears in mice treated as in a. c, 
Quantification of not degranulated (i.e., lacking exteriorized granules, white bars) or 
degranulated mast cells (i.e., presence of exteriorized Av.SRho+ granule structures, indicated 
with yellow arrows in b and grey bars) in DMSO-treated, RTX-treated, Mrgprb2+/+ or 
Mrgprb2mu/mut mice 45 minutes after i.d. injection of vehicle. d, Same experiment as in c 
but 45 minutes after i.d. injection of D. farinae + SEB. e, Changes (Δ) in ear thickness 45 
minutes after i.d. injection of D. farinae + SEB with IgG control isotype (open triangles) or 
with IgG anti-SP (grey triangles) in WT mice. f, 3D representative confocal microscopy 
pictures of Av.SRho fluorescent signal (red) in whole-mounted ears in mice treated as in e. 
g, Quantification of not degranulated or degranulated mast cells in mice treated as in e. h, 
Same experiment as in a but 45 after i.d. injection of capsaicin. i. Same experiment as in b 
but 45 after i.d. injection of capsaicin. j, Same experiment as in d but 45 after i.d. injection 
of capsaicin. Bars = 20 μm. All data are from two independent experiments with the 
following number of mice: (a-d) n = 6 (DMSO Vehicle), n = 5 (RTX Vehicle), n = 5 
(Mrgprb2+/+ Vehicle), n = 6 (Mrgprb2mut/mut Vehicle), n = 7 (DMSO D. farinae + SEB), n = 
7 (RTX D. farinae + SEB), n = 9 (Mrgprb2+/+ D. farinae + SEB), n = 9 (Mrgprb2mut/mut D. 
farinae + SEB); (e-g) n = 7 (IgG control isotype), n = 7 (IgG anti-SP); (h-j) n = 7 (DMSO), 
n = 7 (RTX), n = 7 (Mrgprb2+/+), n = 7 (Mrgprb2mut/mut). Mean ± SEM (a,e,h), mean + 
SEM (c,d,g,j), two-tailed, unpaired t-test, *P<.05 **P<.01 ***P<.001.
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Figure 6. Dermal mast cells and TPRV1+ nociceptors form sensory clusters in the skin that 
respond to D. farinae and SEB.
a, Representative high-resolution 3-D images of the dermis; merged fluorescence of 
Av.SRho (red), GCaMP3 calcium tracer (pseudocolor intensity scale) and collagen structures 
(blue) in Av.SRho-labeled ear pinna of Pirt-GCaMP3 mice 30-60 minutes after i.d. injection 
of vehicle or 1 μM capsaicin or 1 μg D. farinae and 50 ng SEB (alone or in combination). 
White lines identify magnified areas shown in lower images. Bars = 100 μm. b, Mean 
Fluorescence Intensity (MFI) of GCaMP3 fluorescent signal per field of view in mice treated 
as in a. c, Proportion (%) of Av.SRho+ mast cells with exteriorized granule structures (i.e., 
activated to degranulate) per field of view in mice treated as in a. One symbol = one field 
analyzed. (a-c) All data are from three independent experiments with the following number 
of mice: n = 4 (vehicle), n = 5 (capsaicin), n = 5 (D. farinae), n = 3 (SEB), n = 5 (D. farinae 
+ SEB). Mean + SEM, two-tailed, unpaired t-test, **P<.01 ***P<.001. d, Automated 
computational analysis of the minimum distance between modeled Av.SRho+ mast cell 
bodies detected and modeled capsaicin-activated TRPV1+ Pirt-GCaMP3+ sensory neurons. 
e, Examples of modeled Av.SRho+ mast cell bodies forming physical contact with (left) or in 
proximity to (right) modeled capsaicin-activated TRPV1+ Pirt-GCaMP3+ sensory neurons. f, 
Proportion (%) of 453 modeled Av.SRho+ mast cell bodies from the ear pinnae of 3 different 
mice in physical contact with (red), at 1 to 25 μm (black), at 25 to 50 μm (dark grey) or at 
more than 50 μm (light grey) from modeled capsaicin-activated TRPV1+ Pirt-GCaMP3+ 
sensory neurons.
Serhan et al. Page 25
Nat Immunol. Author manuscript; available in PMC 2020 April 07.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
